ConductScience.org, home

Paper31270216

Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.

Bruen R and 10 others. J Pharmacol Exp Ther, 2019. Cited by 47 papers, by iCite.

Cite this record

ConductScience Library. Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators. Papers, record 31270216. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31270216

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.
PubMed
Journal
J Pharmacol Exp Ther
PubMed
Year
2019
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
47
iCite
Relative citation ratio, by iCite
2.01
iCite
Revised in PubMed
2025-03-06
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bruen RRobyn
2Curley SSeán
3Kajani SSarina
4Lynch GGina
5O'Reilly MEMarcella E
6Dillon ETEugène T
7Brennan EPEoin P
8Barry MMary
9Sheehan SStephen
10McGillicuddy FCFiona Chttps://orcid.org/0000-0003-3623-3503
11Belton OOrinahttps://orcid.org/0000-0002-7701-6540

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Apolipoproteins EMajor topic
Inflammation MediatorsMajor topic
LiraglutideMajor topic
PhenotypeMajor topic
Plaque, AtheroscleroticMajor topic
Animals
Chemokines
Disease Progression
Female
Humans
Male
Mice

Source PubMed

Download CSV of topics

Cited by35

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 47 citations.

PMIDTitleJournalYearIn PapersSource
42738873Beyond Weight Loss: Thromboinflammation as a Candidate Mechanism for the Cardiovascular Benefit of GLP-1 Receptor Agonists.Cells2026https://conductscience.org/library/papers/42738873PubMed
42461990GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight.Circ Res2026https://conductscience.org/library/papers/42461990PubMed
42390946A validated, modifiable proteomic score from the EXSCEL trial predicts cardiovascular events in diabetes.JCI Insight2026https://conductscience.org/library/papers/42390946PubMed
42313337Effect of emerging antiobesity and antidiabetic drugs on atherosclerosis.Intern Emerg Med2026https://conductscience.org/library/papers/42313337PubMed
41908941Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs).Drug Des Devel Ther2026https://conductscience.org/library/papers/41908941PubMed
41482411Anti-inflammatory Pathways of Novel Anti-diabetic Therapies. A Literature Review.In Vivo2026https://conductscience.org/library/papers/41482411PubMed
40870496The Role of Myocardial Revascularization in Ischemic Heart Failure in the Era of Modern Optimal Medical Therapy.Medicina (Kaunas)2025https://conductscience.org/library/papers/40870496PubMed
40826119Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies.Diabetol Metab Syndr2025https://conductscience.org/library/papers/40826119PubMed
40721629Protective effects of liraglutide on hypercholesterolemia-associated atherosclerosis involve attenuation of endothelial-monocyte adhesion through down-regulating the LOX-1/NF-κB signaling pathway.Sci Rep2025https://conductscience.org/library/papers/40721629PubMed
40149704Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation.Biomedicines2025https://conductscience.org/library/papers/40149704PubMed
39858999The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.Medicina (Kaunas)2024https://conductscience.org/library/papers/39858999PubMed
39834741Bile acids and incretins as modulators of obesity-associated atherosclerosis.Front Cardiovasc Med2024https://conductscience.org/library/papers/39834741PubMed
39741663Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review.Front Cardiovasc Med2024https://conductscience.org/library/papers/39741663PubMed
39528690Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients.Sci Rep2024https://conductscience.org/library/papers/39528690PubMed
39269643Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction.Heart Fail Rev2025https://conductscience.org/library/papers/39269643PubMed
39062871Microvascular Dysfunction across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications.Int J Mol Sci2024https://conductscience.org/library/papers/39062871PubMed
38970123Excessive accumulation of epicardial adipose tissue promotes microvascular obstruction formation after myocardial ischemia/reperfusion through modulating macrophages polarization.Cardiovasc Diabetol2024https://conductscience.org/library/papers/38970123PubMed
38720777Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease.Front Pharmacol2024https://conductscience.org/library/papers/38720777PubMed
38384297Emerging role of antidiabetic drugs in cardiorenal protection.Front Pharmacol2024https://conductscience.org/library/papers/38384297PubMed
38136567Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?Biomolecules2023https://conductscience.org/library/papers/38136567PubMed

See all 35 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CCL26347PubTator's text mininghttps://conductscience.org/library/genes/6347NCBI Gene
IL1B3553PubTator's text mininghttps://conductscience.org/library/genes/3553NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31270216

GET https://conductscience.org/api/papers/v1/31270216/cited_by?page=2